S1PR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL78848	0.57	19/20
SCHEMBL78846	0.56	19/20
SCHEMBL36045	0.59	18/20
SCHEMBL78850	0.55	18/20
SCHEMBL78672	0.53	18/20
SCHEMBL78849	0.57	17/20
SCHEMBL78847	0.56	17/20
SCHEMBL35944	0.58	15/20
SCHEMBL36110	0.58	15/20
Hydrochloric Acid (SCHEMBL78811)	0.65	14/20
SCHEMBL78673	0.54	14/20
SCHEMBL35933	0.58	13/20
SCHEMBL36123	0.57	13/20
SCHEMBL36206	0.57	13/20
SCHEMBL35848	0.56	13/20
SCHEMBL35951	0.56	13/20
SCHEMBL36013	0.56	13/20
SCHEMBL36218	0.44	13/20
SCHEMBL35626	0.57	12/20
SCHEMBL35942	0.57	12/20

Clinical trials — most relevant to S1PR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
Sphingosine-1-phosphate and Pneumonia	PHASE2/PHASE3	UNKNOWN
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol	PHASE3	ACTIVE_NOT_RECRUITING
Repurposing Siponimod for Alzheimer's Disease	PHASE2	RECRUITING
Fingolimod in Schizophrenia Patients	PHASE2	COMPLETED
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)	PHASE2	WITHDRAWN
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation	PHASE2	ENROLLING_BY_INVITATION
Efficacy and Safety of FTY720 for Acute Stroke	PHASE2	COMPLETED
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.	PHASE1	COMPLETED
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration	PHASE1	UNKNOWN
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors	PHASE1	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis	nan	UNKNOWN
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	nan	SUSPENDED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain	nan	UNKNOWN
Investigation of Inflammation Using [C-11]-CS1P1	nan	ACTIVE_NOT_RECRUITING
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)	nan	UNKNOWN
Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris	nan	NOT_YET_RECRUITING
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Sphingosine-1-phosphate in Asthma	nan	UNKNOWN
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a S1PR1 binder may also engage these)

Protein	Name	Similarity
O08530	—	1.000	O08530 →
P48303	—	1.000	P48303 →
Q5E9P3	—	1.000	Q5E9P3 →
Q9DDK4	—	1.000	Q9DDK4 →
Q9Z0U9	—	0.994	Q9Z0U9 →
Q9PUQ8	—	0.989	Q9PUQ8 →
S1PR3	Sphingosine 1-phosphate receptor 3	0.986	landscape →
Q98895	—	0.980	Q98895 →
O02777	—	0.979	O02777 →
Q9I8K8	—	0.979	Q9I8K8 →
Q333S9	—	0.977	Q333S9 →
P47746	—	0.977	P47746 →
Q71SP5	—	0.977	Q71SP5 →
Q98894	—	0.976	Q98894 →
P20272	—	0.976	P20272 →
P47752	—	0.975	P47752 →
Q5IS73	—	0.975	Q5IS73 →
P56971	—	0.974	P56971 →
Q9PUI7	—	0.974	Q9PUI7 →
P52592	—	0.973	P52592 →
Q801M1	—	0.972	Q801M1 →
CNR1	Cannabinoid receptor 1	0.969	landscape →
Q28905	—	0.968	Q28905 →
P43117	—	0.967	P43117 →
Q56H79	—	0.965	Q56H79 →
P43118	—	0.965	P43118 →
PTGFR	Prostaglandin F2-alpha receptor	0.965	landscape →
S1PR2	Sphingosine 1-phosphate receptor 2	0.965	landscape →
Q8BZP8	—	0.964	Q8BZP8 →
Q99680	—	0.964	Q99680 →